Lymph Node Involvement in Early-Stage Cervical Cancer: Is Lymphangiogenesis a Risk Factor? Results from the MICROCOL Study
Abstract
:Simple Summary
Abstract
1. Introduction
2. Materials and Methods
2.1. Study Design and Patients
2.2. Histopathological Examination
2.3. Immunohistochemistry (IHC)
2.4. Immunohistochemistry Scoring
2.5. Statistical Analysis
3. Results
3.1. Clinicopathological Results
3.2. Treatment
3.3. Risk Factors of Lymph Node Involvement
3.4. Disease-Free Survival (DFS)
4. Discussion
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
Appendix A
References
- Sung, H.; Ferlay, J.; Siegel, R.L.; Laversanne, M.; Soerjomataram, I.; Jemal, A.; Bray, F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J. Clin. 2021, 71, 209–249. [Google Scholar] [CrossRef]
- Sedlis, A.; Bundy, B.N.; Rotman, M.Z.; Lentz, S.S.; Muderspach, L.I.; Zaino, R.J. A randomized trial of pelvic radiation therapy versus no further therapy in selected patients with stage IB carcinoma of the cervix after radical hysterectomy and pelvic lymphadenectomy: A Gynecologic Oncology Group Study. Gynecol. Oncol. 1999, 73, 177–183. [Google Scholar] [CrossRef]
- Ho, C.M.; Chien, T.Y.; Huang, S.H.; Wu, C.J.; Shih, B.Y.; Chang, S.C. Multivariate analysis of the prognostic factors and outcomes in early cervical cancer patients undergoing radical hysterectomy. Gynecol. Oncol. 2004, 93, 458–464. [Google Scholar] [CrossRef] [PubMed]
- Delgado, G.; Bundy, B.; Zaino, R.; Sevin, B.U.; Creasman, W.T.; Major, F. Prospective surgical-pathological study of disease-free interval in patients with stage IB squamous cell carcinoma of the cervix: A Gynecologic Oncology Group study. Gynecol. Oncol. 1990, 38, 352–357. [Google Scholar] [CrossRef]
- Monk, B.J.; Wang, J.; Im, S.; Stock, R.J.; Peters, W.A., III; Liu, P.Y.; Barrett, R.J., II; Berek, J.S.; Souhami, L.; Grigsby, P.W.; et al. Rethinking the use of radiation and chemotherapy after radical hysterectomy: A clinical-pathologic analysis of a Gynecologic Oncology Group/Southwest Oncology Group/Radiation Therapy Oncology Group trial. Gynecol. Oncol. 2005, 96, 721–728. [Google Scholar] [CrossRef] [PubMed]
- Herr, D.; Konig, J.; Heilmann, V.; Koretz, K.; Kreienberg, R.; Kurzeder, C. Prognostic impact of satellite-lymphovascular space involvement in early-stage cervical cancer. Ann. Surg. Oncol. 2009, 16, 128–132. [Google Scholar] [CrossRef] [PubMed]
- Xiong, Y.; Cao, L.P.; Rao, H.L.; Cai, M.Y.; Liang, L.Z.; Liu, J.H. Clinical significance of peritumoral lymphatic vessel density and lymphatic vessel invasion detected by D2-40 immunostaining in FIGO Ib1-IIa squamous cell cervical cancer. Cell Tissue Res. 2012, 348, 515–522. [Google Scholar] [CrossRef]
- Bhatla, N.; Berek, J.S.; Cuello Fredes, M.; Denny, L.A.; Grenman, S.; Karunaratne, K.; Kehoe, S.T.; Konishi, I.; Olawaiye, A.B.; Prat, J.; et al. Revised FIGO staging for carcinoma of the cervix uteri. Int. J. Gynaecol. Obstet. 2019, 145, 129–135. [Google Scholar] [CrossRef]
- Marchiole, P.; Buenerd, A.; Benchaib, M.; Nezhat, K.; Dargent, D.; Mathevet, P. Clinical significance of lympho vascular space involvement and lymph node micrometastases in early-stage cervical cancer: A retrospective case-control surgico-pathological study. Gynecol. Oncol. 2005, 97, 727–732. [Google Scholar] [CrossRef]
- Cibula, D.; Zikan, M.; Slama, J.; Fischerova, D.; Kocian, R.; Germanova, A.; Burgetova, A.; Dusek, L.; Dundr, P.; Gregova, M.; et al. Risk of micrometastases in non-sentinel pelvic lymph nodes in cervical cancer. Gynecol. Oncol. 2016, 143, 83–86. [Google Scholar] [CrossRef]
- Kocian, R.; Slama, J.; Fischerova, D.; Germanova, A.; Burgetova, A.; Dusek, L.; Dundr, P.; Nemejcova, K.; Jarkovsky, J.; Sebestova, S.; et al. Micrometastases in Sentinel Lymph Nodes Represent a Significant Negative Prognostic Factor in Early-Stage Cervical Cancer: A Single-Institutional Retrospective Cohort Study. Cancers 2020, 12, 1438. [Google Scholar] [CrossRef]
- Guani, B.; Balaya, V.; Magaud, L.; Lecuru, F.; Mathevet, P. The Clinical Impact of Low-Volume Lymph Nodal Metastases in Early-Stage Cervical Cancer: The Senticol 1 and Senticol 2 Trials. Cancers 2020, 12, 1061. [Google Scholar] [CrossRef] [PubMed]
- Guani, B.; Dorez, M.; Magaud, L.; Buenerd, A.; Lecuru, F.; Mathevet, P. Impact of micrometastasis or isolated tumor cells on recurrence and survival in patients with early cervical cancer: SENTICOL Trial. Int. J. Gynecol. Cancer 2019, 29, 447–452. [Google Scholar] [CrossRef] [PubMed]
- Sniadecki, M.; Wydra, D.G.; Wojtylak, S.; Wycinka, E.; Liro, M.; Sniadecka, N.; Mrozinska, A.; Sawicki, S. The impact of low volume lymph node metastases and stage migration after pathologic ultrastaging of non-sentinel lymph nodes in early-stage cervical cancer: A study of 54 patients with 4.2 years of follow up. Ginekol. Pol. 2019, 90, 20–30. [Google Scholar] [CrossRef]
- Stany, M.P.; Stone, P.J.; Felix, J.C.; Amezcua, C.A.; Groshen, S.; Ye, W.; Kyser, K.L.; Howard, R.S.; Zahn, C.M.; Muderspach, L.I.; et al. Lymph Node Micrometastases in Early-Stage Cervical Cancer are Not Predictive of Survival. Int. J. Gynecol. Pathol. 2015, 34, 379–384. [Google Scholar] [CrossRef] [PubMed]
- Nica, A.; Gien, L.T.; Ferguson, S.E.; Covens, A. Does small volume metastatic lymph node disease affect long-term prognosis in early cervical cancer? Int. J. Gynecol. Cancer 2020, 30, 285–290. [Google Scholar] [CrossRef] [PubMed]
- Juretzka, M.M.; Jensen, K.C.; Longacre, T.A.; Teng, N.N.; Husain, A. Detection of pelvic lymph node micrometastasis in stage IA2-IB2 cervical cancer by immunohistochemical analysis. Gynecol. Oncol. 2004, 93, 107–111. [Google Scholar] [CrossRef] [PubMed]
- Horn, L.C.; Hentschel, B.; Fischer, U.; Peter, D.; Bilek, K. Detection of micrometastases in pelvic lymph nodes in patients with carcinoma of the cervix uteri using step sectioning: Frequency, topographic distribution and prognostic impact. Gynecol. Oncol. 2008, 111, 276–281. [Google Scholar] [CrossRef]
- Colturato, L.F.; Signorini Filho, R.C.; Fernandes, R.C.; Gebrim, L.H.; Oliani, A.H. Lymph node micrometastases in initial stage cervical cancer and tumoral recurrence. Int. J. Gynaecol. Obstet. 2016, 133, 69–75. [Google Scholar] [CrossRef] [PubMed]
- Buda, A.; Casarin, J.; Mueller, M.; Fanfani, F.; Zapardiel, I.; Mereu, L.; Puppo, A.; De Ponti, E.; Adorni, M.; Ferrari, D.; et al. The impact of low-volume metastasis on disease-free survival of women with early-stage cervical cancer. J. Cancer Res. Clin. Oncol. 2021, 147, 1599–1606. [Google Scholar] [CrossRef] [PubMed]
- Lecuru, F.; Mathevet, P.; Querleu, D.; Leblanc, E.; Morice, P.; Darai, E.; Marret, H.; Magaud, L.; Gillaizeau, F.; Chatellier, G.; et al. Bilateral negative sentinel nodes accurately predict absence of lymph node metastasis in early cervical cancer: Results of the SENTICOL study. J. Clin. Oncol. 2011, 29, 1686–1691. [Google Scholar] [CrossRef]
- Bats, A.S.; Mathevet, P.; Buenerd, A.; Orliaguet, I.; Mery, E.; Zerdoud, S.; Le Frere-Belda, M.A.; Froissart, M.; Querleu, D.; Martinez, A.; et al. The sentinel node technique detects unexpected drainage pathways and allows nodal ultrastaging in early cervical cancer: Insights from the multicenter prospective SENTICOL study. Ann. Surg. Oncol. 2013, 20, 413–422. [Google Scholar] [CrossRef]
- Mathevet, P.; Lecuru, F.; Uzan, C.; Boutitie, F.; Magaud, L.; Guyon, F.; Querleu, D.; Fourchotte, V.; Baron, M.; Bats, A.S.; et al. Sentinel lymph node biopsy and morbidity outcomes in early cervical cancer: Results of a multicentre randomised trial (SENTICOL-2). Eur. J. Cancer 2021, 148, 307–315. [Google Scholar] [CrossRef]
- Stacker, S.A.; Williams, S.P.; Karnezis, T.; Shayan, R.; Fox, S.B.; Achen, M.G. Lymphangiogenesis and lymphatic vessel remodelling in cancer. Nat. Rev. Cancer 2014, 14, 159–172. [Google Scholar] [CrossRef]
- Yetkin-Arik, B.; Kastelein, A.W.; Klaassen, I.; Jansen, C.; Latul, Y.P.; Vittori, M.; Biri, A.; Kahraman, K.; Griffioen, A.W.; Amant, F.; et al. Angiogenesis in gynecological cancers and the options for anti-angiogenesis therapy. Biochim. Biophys. Acta Rev. Cancer 2021, 1875, 188446. [Google Scholar] [CrossRef]
- Garnier, L.; Gkountidi, A.O.; Hugues, S. Tumor-Associated Lymphatic Vessel Features and Immunomodulatory Functions. Front. Immunol. 2019, 10, 720. [Google Scholar] [CrossRef] [Green Version]
- Birner, P.; Obermair, A.; Schindl, M.; Kowalski, H.; Breitenecker, G.; Oberhuber, G. Selective immunohistochemical staining of blood and lymphatic vessels reveals independent prognostic influence of blood and lymphatic vessel invasion in early-stage cervical cancer. Clin. Cancer Res. 2001, 7, 93–97. [Google Scholar]
- Schoppmann, S.F.; Schindl, M.; Breiteneder-Geleff, S.; Soleima, A.; Breitenecker, G.; Karner, B.; Birner, P. Inflammatory stromal reaction correlates with lymphatic microvessel density in early-stage cervival cancer. Anticancer Res. 2001, 21, 3419–3423. [Google Scholar]
- Gombos, Z.; Xu, X.; Chu, C.S.; Zhang, P.J.; Acs, G. Peritumoral lymphatic vessel density and vascular endothelial growth factor C expression in early-stage squamous cell carcinoma of the uterine cervix. Clin. Cancer Res. 2005, 11, 8364–8371. [Google Scholar] [CrossRef] [Green Version]
- Longatto-Filho, A.; Pinheiro, C.; Pereira, S.M.; Etlinger, D.; Moreira, M.A.; Jube, L.F.; Queiroz, G.S.; Baltazar, F.; Schmitt, F.C. Lymphatic vessel density and epithelial D2-40 immunoreactivity in pre-invasive and invasive lesions of the uterine cervix. Gynecol. Oncol. 2007, 107, 45–51. [Google Scholar] [CrossRef]
- Zaganelli, F.L.; Carvalho, F.M.; Almeida, B.G.; Bacchi, C.E.; Goes, J.C.; Calil, M.A.; Baracat, E.C.; Carvalho, J.P. Intratumoral lymphatic vessel density and clinicopathologic features of patients with early-stage cervical cancer after radical hysterectomy. Int. J. Gynecol. Cancer 2010, 20, 1225–1231. [Google Scholar] [CrossRef]
- Sotiropoulou, N.; Bravou, V.; Kounelis, S.; Damaskou, V.; Papaspirou, E.; Papadaki, H. Tumour expression of lymphangiogenic growth factors but not lymphatic vessel density is implicated in human cervical cancer progression. Pathology 2010, 42, 629–636. [Google Scholar] [CrossRef]
- Bats, A.S.; Frati, A.; Froissart, M.; Orliaguet, I.; Querleu, D.; Zerdoud, S.; Leblanc, E.; Gauthier, H.; Uzan, C.; Deandreis, D.; et al. Feasibility and performance of lymphoscintigraphy in sentinel lymph node biopsy for early cervical cancer: Results of the prospective multicenter SENTICOL study. Ann. Nucl. Med. 2015, 29, 63–70. [Google Scholar] [CrossRef] [Green Version]
- Benoit, L.; Balaya, V.; Guani, B.; Bresset, A.; Magaud, L.; Bonsang-Kitzis, H.; Ngo, C.; Mathevet, P.; Lecuru, F. Nomogram Predicting the Likelihood of Parametrial Involvement in Early-Stage Cervical Cancer: Avoiding Unjustified Radical Hysterectomies. J. Clin. Med. 2020, 9, 2121. [Google Scholar] [CrossRef]
- Cohen, P.A.; Jhingran, A.; Oaknin, A.; Denny, L. Cervical cancer. Lancet 2019, 393, 169–182. [Google Scholar] [CrossRef]
- Saad, R.S.; Kordunsky, L.; Liu, Y.L.; Denning, K.L.; Kandil, H.A.; Silverman, J.F. Lymphatic microvessel density as prognostic marker in colorectal cancer. Mod. Pathol. 2006, 19, 1317–1323. [Google Scholar] [CrossRef] [Green Version]
- Ran, S.; Volk, L.; Hall, K.; Flister, M.J. Lymphangiogenesis and lymphatic metastasis in breast cancer. Pathophysiology 2010, 17, 229–251. [Google Scholar] [CrossRef] [Green Version]
- Sipos, B.; Kojima, M.; Tiemann, K.; Klapper, W.; Kruse, M.L.; Kalthoff, H.; Schniewind, B.; Tepel, J.; Weich, H.; Kerjaschki, D.; et al. Lymphatic spread of ductal pancreatic adenocarcinoma is independent of lymphangiogenesis. J. Pathol. 2005, 207, 301–312. [Google Scholar] [CrossRef]
- Cabel, L.; Bidard, F.C.; Servois, V.; Cacheux, W.; Mariani, P.; Romano, E.; Minsat, M.; Bieche, I.; Farkhondeh, F.; Jeannot, E.; et al. HPV circulating tumor DNA to monitor the efficacy of anti-PD-1 therapy in metastatic squamous cell carcinoma of the anal canal: A case report. Int. J. Cancer 2017, 141, 1667–1670. [Google Scholar] [CrossRef] [Green Version]
- Bernard-Tessier, A.; Jeannot, E.; Guenat, D.; Debernardi, A.; Michel, M.; Proudhon, C.; Vincent-Salomon, A.; Bieche, I.; Pierga, J.Y.; Buecher, B.; et al. Clinical Validity of HPV Circulating Tumor DNA in Advanced Anal Carcinoma: An Ancillary Study to the Epitopes-HPV02 Trial. Clin. Cancer Res. 2019, 25, 2109–2115. [Google Scholar] [CrossRef]
- Jeannot, E.; Latouche, A.; Bonneau, C.; Calmejane, M.A.; Beaufort, C.; Ruigrok-Ritstier, K.; Bataillon, G.; Larbi Cherif, L.; Dupain, C.; Lecerf, C.; et al. Circulating HPV DNA as a Marker for Early Detection of Relapse in Patients with Cervical Cancer. Clin. Cancer Res. 2021, 27, 5869–5877. [Google Scholar] [CrossRef] [PubMed]
Characteristics | Patient N. | % | |
---|---|---|---|
Age | 75 | Median 42.3 Range 23–85 | |
Surgery type | |||
LPS | 63 | 84 | |
LPT | 12 | 16 | |
Stage | |||
IA2 | 4 | 5.3 | |
IB1 | 71 | 94.7 | |
Histological type | |||
Adenocarcinoma | 19 | 25.3 | |
Squamous | 54 | 72 | |
Adenosquamous | 2 | 2.7 | |
Grade | |||
G1 | 23 | 30.6 | |
G2 | 28 | 37.4 | |
G3 | 16 | 21.4 | |
n.d. | 8 | 10.6 | |
PNI | |||
pos | 1 | 1.3 | |
neg | 68 | 90.7 | |
n.d. | 6 | 8 |
Factors | N. with PLNM N. Tot (%) | Association with PLNM (p-Value U) | Association with PLNM (p-Value M) |
---|---|---|---|
Age | 0.18 | 0.10 | |
<50 | 10/54 (18.5%) | ||
50–70 | 2/16 (12.5%) | ||
>70 | 2/5 (40%) | ||
Surgical approach | 0.73 | ||
LPS | 10/63 (16.6%) | ||
LPT | 4/12 (33.3%) | ||
Grade | 0.84 | ||
G1 | 4/23 (17.4%) | ||
G2 | 5/28 (17.8%) | ||
G3 | 4/16 (25%) | ||
n.d. | 1/8 (12.5%) | ||
Size | 0.36 | ||
2 cm | 4/36 (11.1%) | ||
>2 cm | 8/32 (25%) | ||
n.d. | 2/7 (28.6%) | ||
Type | 0.65 | ||
Squamous | 11/54 (20.3%) | ||
Adenocarcinoma | 3/19 (15.8%) | ||
Adenosquamous | 0/2 (0%) | ||
Stromal invasion | 0.11 | 0.96 | |
<3 mm | 0/3 (0%) | ||
3–8 mm | 2/14 (14.3%) | ||
>8 mm | 7/23 (30.4%) | ||
n.d. | 5/35 (14.3%) | ||
LVSI (H/E staining) | 0.0009 | 0.03 | |
Positive | 11/29 (38%) | ||
Negative | 3/44 (7%) |
N+ | N− | Total | p Value (U) | |
---|---|---|---|---|
H/E Staining | ||||
LVSI+ | 11 | 18 | 29 | |
LVSI− | 3 | 41 | 44 | 0.0009 |
D2-40 | ||||
LVSI+ | 8 | 26 | 34 | |
LVSI− | 5 | 34 | 39 | 0.23 |
Markers | p Value | ||||
---|---|---|---|---|---|
Ki 67 | Mean ± st.d. | Median | N. | n.d. | 0.45 |
LN+ | 63.38 ± 19.74 | 69 (34–95) | 13 | 1 | |
LN− | 67.89 ± 17.3 | 64 (15–96) | 59 | 2 | |
CD31 | Mean ± st.d. | Median | N. | n.d. | 0.28 |
LN+ | 13.32 ± 10.19 | 11.3 (3.33–45) | 14 | 2 | |
LN− | 11.34 ± 4.83 | 10.6 (3.75–24.4) | 59 | 0 | |
D2-40 Ab | 0 | 1 | 2 | n.d. | 0.43 |
LN+ | 10 | 1 | 2 | 1 | |
LN− | 34 | 7 | 18 | 2 | |
VEGF-C | 0 | 1 | 2–3 | n.d. | 0.31 |
LN+ | 5 | 5 | 4 | 0 | |
LN− | 27 | 23 | 7 | 4 |
Factors | Number of Recurrences | Kaplan–Meier p Value | Cox Regression p Value |
---|---|---|---|
LN status | 0.25 | ||
MAC | 0/4 (0%) | ||
MIC | 1/5 (20%) | ||
ITC | 1/5 (20%) | ||
N0 | 3/61 (5%) | ||
Tumor type | 0.63 | ||
Squamous | 3/56 (5.3%) | ||
Adenocarcinoma | 2/17 (11.7%) | ||
Adenosquamous | 0/2 (0%) | ||
Age | 0.07 | 0.91 | |
<50 | 1/54 (1.8%) | ||
>50 | 3/21 (14.2%) | ||
Tumoral diameter | 1 | ||
<2 cm | 2/36 (5.5%) | ||
>2 cm | 3/32 (9.3%) | ||
LVSI (H/E) | 0.17 | 0.42 | |
Negative | 4/30 (13.3%) | ||
Positive | 1/45 (2.2%) | ||
LVSI (D2-40) | 1 | ||
Negative | 4/39 (10.2%) | ||
Positive | 1/34 (2.9%) | ||
VEGF-C | 1 | ||
0 | 3/32 (9.3%) | ||
1 | 1/28 (3.5%) | ||
2–3 | 1/11 (9%) | ||
KI-67 | Mean value | 0.64 | |
If recurrence | 72.04 ± 9.33 | ||
If not recurrence | 63.61 ± 14.99 | ||
CD-31 | Mean value | 0.2 | |
If recurrence | 17.10 ± 3.87 | ||
If not recurrence | 11.20 ± 9.37 |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Tantari, M.; Bogliolo, S.; Morotti, M.; Balaya, V.; Bouttitie, F.; Buenerd, A.; Magaud, L.; Lecuru, F.; Guani, B.; Mathevet, P.; et al. Lymph Node Involvement in Early-Stage Cervical Cancer: Is Lymphangiogenesis a Risk Factor? Results from the MICROCOL Study. Cancers 2022, 14, 212. https://doi.org/10.3390/cancers14010212
Tantari M, Bogliolo S, Morotti M, Balaya V, Bouttitie F, Buenerd A, Magaud L, Lecuru F, Guani B, Mathevet P, et al. Lymph Node Involvement in Early-Stage Cervical Cancer: Is Lymphangiogenesis a Risk Factor? Results from the MICROCOL Study. Cancers. 2022; 14(1):212. https://doi.org/10.3390/cancers14010212
Chicago/Turabian StyleTantari, Matteo, Stefano Bogliolo, Matteo Morotti, Vincent Balaya, Florent Bouttitie, Annie Buenerd, Laurent Magaud, Fabrice Lecuru, Benedetta Guani, Patrice Mathevet, and et al. 2022. "Lymph Node Involvement in Early-Stage Cervical Cancer: Is Lymphangiogenesis a Risk Factor? Results from the MICROCOL Study" Cancers 14, no. 1: 212. https://doi.org/10.3390/cancers14010212